Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting

Novartis (NOVN: VX), Boehringer Ingelheim and Celgene (Nasdaq: CELG) have presented positive data on their dermatology products at the American Academy of Dermatology meeting in San Francisco this weekend.

Novartis' Cosentyx superior to Stelara

New  data from Novartis showed that its Cosentyx (secukinumab) is significantly superior to Stelara (ustekinumab), a widely-used biologic, in achieving clear or almost-clear skin for psoriasis patients. Cosentyx met the primary endpoint in a Phase IIIb study of showing superiority to Stelara as assessed by the Psoriasis Area Severity Index (PASI) 90 response, which is clear to almost-clear skin, at week 16.